comparemela.com

Latest Breaking News On - Neurogene inc - Page 3 : comparemela.com

Neurogene (NASDAQ:NGNE) Earns Outperform Rating from Leerink Partnrs

Leerink Partnrs reaffirmed their outperform rating on shares of Neurogene (NASDAQ:NGNE – Free Report) in a report issued on Monday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Neurogene’s Q1 2024 earnings at ($1.19) EPS. Other research analysts have also issued research reports about the stock. SVB Leerink started coverage on shares of Neurogene […]

Leerink partnrsStifel nicolausWilliam blairGreat point partnersCapital managementNeurogene incPrivium fund management united kingdom ltdFree reportFund management united kingdom ltdPartners managementGet free reportNeurogene dailyNasdaq ngneReiterated rating

Neurogene (NASDAQ:NGNE) Rating Reiterated by Leerink Partnrs

Neurogene (NASDAQ:NGNE) Rating Reiterated by Leerink Partnrs
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

William blairStifel nicolausLeerink partnrsNeurogene incNeurogene company profileCapital managementGreat point partnersPrivium fund management united kingdom ltdGet free reportFund management united kingdom ltdPartners managementNeurogene daily

Neurogene (NASDAQ:NGNE) Now Covered by Analysts at SVB Leerink

Neurogene (NASDAQ:NGNE) Now Covered by Analysts at SVB Leerink
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Stifel nicolausWilliam blairGreat point partnersNeurogene company profileNeurogene incCapital managementGet free reportPoint partnersAvidity partners managementNeurogene daily

Neurogene Inc Files SEC Form 8-K Report

has released an update. Neurogene Inc., a biotech firm incorporated in Delaware, has filed a Form 8-K with the SEC, indicatin.

United statesNeurogene incReaking news

Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting

NGN-401 has been generally well-tolerated by three patients with multiple months of follow-up .

United statesUnited kingdomRachel mcminnNeurogene incCompany annual report on formAmerican society for geneExchange commissionAmerican societyCell therapyChief executive officerPoster presentationPreliminary safety resultsNovel regulated gene therapyRett syndromeExhibit hallPrivate securities litigation reform act

vimarsana © 2020. All Rights Reserved.